<DOC>
	<DOCNO>NCT01215266</DOCNO>
	<brief_summary>The purpose study evaluate use Sorafenib additionally gemcitabine cisplatin bladder cancer .</brief_summary>
	<brief_title>Sorafenib Urothelium Cancer Bladder</brief_title>
	<detailed_description>A control , double-blind , randomize study evaluate influence Sorafenib bladder cancer patient additionally chemotherapy gemcitabine cisplatin compare placebo .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Men Women &gt; 18 year Condition ECOG ( Eastern Cooperative Oncology Group ) 01 Life expectancy least 12 week Women conceptional age : negative pregnancy test adequate contraception ( oral contraceptive , spiral ) ; men adequate contraception man ( condom use ) 3 month discontinuation therapy sorafenib Histologically cytologically proven urothelial carcinoma bladder upper urinary tract Locally advance metastatic urothelial carcinoma bladder upper urinary tract ( T3b , T4/ N+/M+ ) At least one unidimensional measurable lesion CT ( Computed Tomography ) MRI ( Magnetic resonance imaging ) accord RECIST ( Response Evaluation Criteria Solid Tumors ) criteria Adequate hematologic , renal , hepatic coagulationphysiological function Leukocytes &gt; 1.500 cell /ml ( per milliliter ) Hemoglobin &gt; 9g/dl ( gram per deciliter ) Platelet &gt; 100000 /ml Serum creatinine &lt; 2 x upper limit normal creatinine clearance â‰¥ 45 ml/min ( milliliter per minute ) Total Bilirubin &lt; 1,5 x upper limit normal GOT/GPT ( glutamateoxalacetatetransaminase/glutamatepyruvatetransaminase ) &lt; 2,5 x upper limit normal , liver metastasis &lt; 5x upper limit normal alkaline phosphates &lt; 5 x upper limit normal Amylase/ Lipase &lt; 1,5 x upper limit normal INR ( International Normalized Ratio ) und PTT ( Partial Thromboplastin Time ) &lt; 1,5 x upper limit normal Informing patient study present write consent participate clarification accordance stipulation AMG ( german drug law ) , principles Ethics Committee ( `` inform consent '' ) . Absence inclusion criterion Dialysis nephrectomy Patients brain tumor / brain metastasis Previous exist serious cardiovascular ( grade III IV accord NYHA ( New York Heart Association ) ) disease , active angina pectoris ischemia , myocardial infarction within 6 month prior enrollment , patient serious cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Patients uncontrolled high blood pressure , systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mmHg despite optimal medical treatment Patients thrombotic embolic event stroke pulmonary embolism Patients recently know bleeding diathesis Known significant neurological psychiatric disease include dementia epileptic seizure Serious inflammatory eye disease , hear impairment Pulmonary ( pO2 ( Blood oxygen ) &lt; 60 mm Hg ( Millimeters mercury ) ) , hematopoietic ( eg ( exempli gratia ) severe bone marrow aplasia ) , hepatic renal disease Patients poorly control diabetes mellitus Serious bacterial fungal infection ( &gt; Grade 2 NCICTC ( National Cancer InstituteCommon Terminology Criteria ) Version 3 ) chronic hepatitis B C , HIV ( human immunodeficiency virus ) infection Autoimmune disease Allergic reaction use respect drug prior organ transplantation prior autologous bone marrow transplant stem cell transfer within last 4 month study Manifesto , second malignancy malignancy within past 5 year ( except basal cell carcinoma , carcinoma situ cervix , incidental prostate carcinoma ) Pregnancy breastfeed Lack cooperation ability cooperate , predictable problem aftercare , psychiatric disorder , substance abuse , lack capacity patient Participation treatment study last 4 week Previous treatment chemotherapy immunotherapy Simultaneous treatment antitumor therapy study start Intravesical chemotherapy within last 4 week Irradiation within last 4 week Previous radiation therapy , irradiated assessment tumor response use lesion Complex operation , open biopsy significant injury within last 4 week study Serious wound heal disorder , ulcer bone fracture last 4 week study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Bladder cancer</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Urothelium cancer</keyword>
</DOC>